Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/jpp.JPP_2_17 http://scihub22266oqcxt.onion/10.4103/jpp.JPP_2_17 C5497404!5497404!28706403     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Pharmacol+Pharmacother 2017 ; 8 (2): 77-9 Nephropedia Template TP {{tp|p=28706403|t=2017. Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia |pdf=|usr=}}{{28706403}} gab.com Text Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia JO: J Pharmacol Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=28706403 #FOAvip Dalbavancin is a lipoglycopeptide with a long half-life that allows infrequent dosing. It is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible organisms, including Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). Although this agent has been used off-label clinically, there are minimal data in infections outside the current indications. We report a case of a 28-year-old nonadherent male with HIV presenting with pneumonia due to MRSA that was treated with dalbavancin. The patient was admitted to the hospital with classic pneumonia symptoms, and sputum cultures and bronchoalveolar lavage grew MRSA. Other infections were ruled out. The patient was initially treated with vancomycin, but subtherapeutic concentrations prompted a change to dalbavancin upon discharge. The patient was readmitted 11 days later with the complaints of hemoptysis and shortness of breath, with unchanged imaging. However, no evidence of MRSA was found at this time. Utility of dalbavancin for other disease states has profound implications, particularly in patients with poor medication adherence. Twit Text FOAVip Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia ????J Pharmacol Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=28706403 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28706403 #FOAvip English Wikipedia <ref>{{Cite pmid|28706403}}</ref> Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia #MMPMID28706403 Barber KE; Tirmizi A; Finley R; Stover KR J Pharmacol Pharmacother 2017[Apr]; 8 (2): 77-9 PMID28706403show ga Dalbavancin is a lipoglycopeptide with a long half-life that allows infrequent dosing. It is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible organisms, including Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). Although this agent has been used off-label clinically, there are minimal data in infections outside the current indications. We report a case of a 28-year-old nonadherent male with HIV presenting with pneumonia due to MRSA that was treated with dalbavancin. The patient was admitted to the hospital with classic pneumonia symptoms, and sputum cultures and bronchoalveolar lavage grew MRSA. Other infections were ruled out. The patient was initially treated with vancomycin, but subtherapeutic concentrations prompted a change to dalbavancin upon discharge. The patient was readmitted 11 days later with the complaints of hemoptysis and shortness of breath, with unchanged imaging. However, no evidence of MRSA was found at this time. Utility of dalbavancin for other disease states has profound implications, particularly in patients with poor medication adherence. äDalbavancin Use for the Treatment of Methicillin-resistant Staphylococ(epmc).pdf DeepDyve Pubget Overpricing